Communications Biology (Aug 2022)

A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ

  • Man Wang,
  • Rong Xu,
  • Xiaoli Liu,
  • Ling Zhang,
  • Siyan Qiu,
  • Yuting Lu,
  • Peng Zhang,
  • Ming Yan,
  • Jing Zhu

DOI
https://doi.org/10.1038/s42003-022-03776-0
Journal volume & issue
Vol. 5, no. 1
pp. 1 – 18

Abstract

Read online

The co-crystal berberine-ibuprofen is an effective agent for treating obesity through a reduction of the activity of the non-canonical I κB kinases, IKKε and TBK1.